Description and Brand Names

Drug information provided by: Merative, Micromedex®

US Brand Name

  1. Jakafi

Descriptions


Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Myelofibrosis is a life-threatening bone marrow problem which is manifested by the following symptoms: enlarged spleen (splenomegaly), severe itching, fever, night sweats, weight loss, bone pain, or unusual tiredness or weakness. It is also used to treat polycythemia vera in patients who have been previously treated with hydroxyurea that did not work well.

Ruxolitinib is also used to treat acute graft-versus-host disease (aGVHD) in patients who have been treated with other medicines (eg, steroids) that did not work well. It is also used to treat chronic graft-versus-host disease (cGVHD) in patients who have been treated with 1 or 2 previous treatments that did not work well.

This medicine is available only with your doctor's prescription.

This product is available in the following dosage forms:

  • Tablet

From Mayo Clinic to your inbox

Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Portions of this document last updated: Sept. 01, 2024

Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.